Exelixis, Inc. (EXEL)
71.77
+0.03
(+0.04%)
USD |
NASDAQ |
Nov 10, 09:36
Exelixis Cash and Short Term Investments (Quarterly) : 892.02M for Sept. 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 892.02M |
| June 30, 2026 | 839.38M |
| March 31, 2026 | 777.21M |
| December 31, 2025 | 1.059B |
| September 30, 2025 | 988.54M |
| June 30, 2025 | 791.10M |
| March 31, 2025 | 1.031B |
| December 31, 2024 | 1.111B |
| September 30, 2024 | 1.189B |
| June 30, 2024 | 1.002B |
| March 31, 2024 | 963.26M |
| December 31, 2023 | 995.30M |
| September 30, 2023 | 1.103B |
| June 30, 2023 | 1.267B |
| March 31, 2023 | 1.313B |
| December 31, 2022 | 1.308B |
| September 30, 2022 | 1.547B |
| June 30, 2022 | 1.535B |
| March 31, 2022 | 1.570B |
| December 31, 2021 | 1.467B |
| September 30, 2021 | 1.403B |
| June 30, 2021 | 1.347B |
| March 31, 2021 | 1.185B |
| December 31, 2020 | 1.207B |
| September 30, 2020 | 1.188B |
| Date | Value |
|---|---|
| June 30, 2020 | 1.213B |
| March 31, 2020 | 954.37M |
| December 31, 2019 | 852.24M |
| September 30, 2019 | 760.67M |
| June 30, 2019 | 822.12M |
| March 31, 2019 | 799.65M |
| December 31, 2018 | 693.33M |
| September 30, 2018 | 635.13M |
| June 30, 2018 | 500.43M |
| March 31, 2018 | 427.42M |
| December 31, 2017 | 388.28M |
| September 30, 2017 | 367.10M |
| June 30, 2017 | 349.26M |
| March 31, 2017 | 424.27M |
| December 31, 2016 | 419.80M |
| September 30, 2016 | 319.68M |
| June 30, 2016 | 328.12M |
| March 31, 2016 | 322.12M |
| December 31, 2015 | 167.06M |
| September 30, 2015 | 197.81M |
| June 30, 2015 | 82.71M |
| March 31, 2015 | 113.35M |
| December 31, 2014 | 156.50M |
| September 30, 2014 | 204.21M |
| June 30, 2014 | 245.73M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 736.01M |
| Alnylam Pharmaceuticals, Inc. | 3.587B |
| Cytokinetics, Inc. | 1.133B |
| Gilead Sciences, Inc. | 7.952B |
| Ionis Pharmaceuticals, Inc. | 1.884B |